SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Microcap & Penny Stocks : IMMD - ImmuDyne
IMMD 0.215-2.1%Jun 21 4:00 PM EDT

 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: paul gambuto who wrote (1239)7/19/1999 12:27:00 PM
From: paul gambuto  Read Replies (1) of 1249
 
news out today. and the price moves up.
paulie

HOUSTON--(BUSINESS WIRE)--July 19, 1999--ImmuDyne Inc. (OTC BB:IMMD)(''ImmuDyne'' or the ''Company''), a Texas-based company specializing in scientifically formulated dietary supplements and skin care cosmetics, announced the launch of five new nutritional products. The products are:

ArthroForce - a proprietary and patent pending dietary supplement consisting of Collagen Type II, Glucosamine Sulfate and Chondroitin Sulfate to support healthy joints for those who suffer from both rheumatoid arthritis and osteoarthritis.
CardioShield - a proprietary and patented dietary supplement that contains various natural ingredients including Niacin and Beta-1,3-D-glucan which have been shown to help maintain normal cholesterol levels.
VascularForce - a proprietary dietary supplement that contains various natural ingredients as well as Folic acid and Vitamin B12, which have been shown to lower homocysteine levels in many clinical studies.
ProstaForce - a dietary supplement containing saw palmetto extract, nettle extract and lycopene to maintain a healthy prostate.
MemoryForce - a dietary supplement that contains Huperzine A in addition to other natural ingredients that help in supporting mental acuity and memory functions.
Dr. Nino Sorgente, senior vice president of research and development, stated that ''The launch of these new products manifests ImmuDyne's new direction and focus as a quality cosmeceutical and nutriceutical company.'' The Company stated that these new products are available at finer health food stores and pharmacies or by calling the Company direct at 888/246-6839.

The Company also announced that Leonid G. Ber, M.D., vice president of research and development has resigned to pursue other opportunities. Dr. Sorgente assumed the responsibilities held by Dr. Ber. Dr. Sorgente has been with ImmuDyne for one year. He is a former professor at the University of Southern California where he taught biochemistry and did research in various areas of biochemistry. Additionally, Dr. Sorgente was a visiting professor at Childrens Hospital of Los Angeles where he did research on the penetration of various substances through the skin and a visiting scientist for Hoffmann-La Roche in the area of molecular biology. He received his Ph.D. in Biochemistry from Loyola University, School of Medicine.

''Safe Harbor'' Statement under the Private Securities Litigation Reform Act of 1995. The statements which are not facts contained in the release are forward-looking statements that involve risks and uncertainties, some of which are outside the Company's control, and accordingly, actual results may differ materially. Factors that might cause such a difference include, but are not limited to, implementation of the Company's strategies, the impact of competitive and industry developments, the results of research and development efforts by the Company, product development by the Company and customer acceptance of the Company's products and services.

ImmuDyne is a Texas-based a company, specializing in scientifically formulated dietary supplements and skin care cosmetics. The common stock of ImmuDyne is traded on the OTC Bulletin Board under the symbol IMMD. For investment information, contact the Company at 713/783-2043.

Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext